The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival

被引:64
作者
Shen, Xia-Bo [1 ,2 ]
Zhang, Yu-Xin [1 ,2 ]
Wang, Wei [2 ]
Pan, Yue-Yin [1 ,2 ]
机构
[1] Anhui Med Univ, Anhui Prov Hosp, Dept Med Oncol, Hefei, Anhui, Peoples R China
[2] USTC, Affiliated Hosp 1, Dept Med Oncol, Hefei, Anhui, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2019年 / 25卷
关键词
Body Mass Index; Nutrition Assessment; Small Cell Lung Carcinoma; Treatment Outcome; BODY-MASS INDEX; PROGNOSTIC-FACTORS; ASSOCIATION; COMBINATION; RESECTION; OUTCOMES;
D O I
10.12659/MSM.917968
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a prognostic factor in patients who have some types of malignant tumors. The aim of this study was to investigate the prognostic significance of the HALP score in patients with small cell lung cancer (SCLC) before first-line treatment with etoposide. Material/Methods: A retrospective study included 178 patients with SCLC who received first-line chemotherapy with etoposide between September 2015 and May 2019. The baseline clinical characteristics and blood parameters were recorded. Univariate and multivariate analysis and Kaplan-Meier plots were used to identify the factors associated with progression-free survival (PFS). Results: The optimal cut-off values of the HALP score was determined by X-tile software to be 25.8. Univariate and multivariate analysis showed that in 178 patients, the HALP score, body mass index (BMI), and serum albumin levels had no prognostic significance. In the patient age group <65 years, a BMI >= 24 kg/m(2) was an independent prognostic factor (HR, 1.943; 95% CI, 1.251-3.018) (P=0.003). In the patient age group >= 65 years, a HALP score >25.8 was an independent positive prognostic factor for outcome following first-line treatment with etoposide (HR, 0.483; 95% CI, 0.270-0.865) (P=0.014). Conclusions: In patients <65 years with SCLC who underwent first-line treatment with etoposide, a BMI >= 24 kg/m(2) an independent prognostic factor, and in patients >= 65 years, a HALP score >25.8 was an independent predictor of improved outcome, associated with increased PFS.
引用
收藏
页码:5630 / 5639
页数:10
相关论文
共 27 条
[1]   X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization [J].
Camp, RL ;
Dolled-Filhart, M ;
Rimm, DL .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7252-7259
[2]   Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study [J].
Chen, Xiao-Long ;
Xue, Lian ;
Wang, Wei ;
Chen, Hai-Ning ;
Zhang, Wei-Han ;
Liu, Kai ;
Chen, Xin-Zu ;
Yang, Kun ;
Zhang, Bo ;
Chen, Zhi-Xin ;
Chen, Jia-Ping ;
Zhou, Zong-Guang ;
Hu, Jian-Kun .
ONCOTARGET, 2015, 6 (38) :41370-41382
[3]   The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma [J].
Cong, Lihong ;
Hu, Likuan .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 46 :75-79
[4]   A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable [J].
Cortellini, Alessio ;
Bersanelli, Melissa ;
Buti, Sebastiano ;
Cannita, Katia ;
Santini, Daniele ;
Perrone, Fabiana ;
Giusti, Raffaele ;
Tiseo, Marcello ;
Michiara, Maria ;
Di Marino, Pietro ;
Tinari, Nicola ;
De Tursi, Michele ;
Zoratto, Federica ;
Veltri, Enzo ;
Marconcini, Riccardo ;
Malorgio, Francesco ;
Russano, Marco ;
Anesi, Cecilia ;
Zeppola, Tea ;
Filetti, Marco ;
Marchetti, Paolo ;
Botticelli, Andrea ;
Cappellini, Gian Carlo Antonini ;
De Galitiis, Federica ;
Vitale, Maria Giuseppa ;
Rastelli, Francesca ;
Pergolesi, Federica ;
Berardi, Rossana ;
Rinaldi, Silvia ;
Tudini, Marianna ;
Silva, Rosa Rita ;
Pireddu, Annagrazia ;
Atzori, Francesco ;
Chiari, Rita ;
Ricciuti, Biagio ;
De Giglio, Andrea ;
Iacono, Daniela ;
Gelibter, Alain ;
Occhipinti, Mario Alberto ;
Parisi, Alessandro ;
Porzio, Giampiero ;
Fargnoli, Maria Concetta ;
Ascierto, Paolo Antonio ;
Ficorella, Corrado ;
Natoli, Clara .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[5]   Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia? [J].
Filliatre-Clement, Lauriane ;
Broseus, Julien ;
Muller, Marc ;
Hosseini, Kossar ;
Rotonda, Christine ;
Schirmer, Luciane ;
Roth-Guepin, Gabrielle ;
Bonmati, Caroline ;
Feugier, Pierre ;
Bene, Marie-Christine ;
Perrot, Aurore .
HEMATOLOGICAL ONCOLOGY, 2019, 37 (01) :80-84
[6]   Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer [J].
Go, Se-Il ;
Jeon, Hankyu ;
Park, Sung Woo ;
Kang, Myoung Hee ;
Kim, Hoon-Gu ;
Lee, Gyeong-Won .
THORACIC CANCER, 2018, 9 (11) :1483-1491
[7]   Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors [J].
Hsu, Chia-Lin ;
Chen, Kuan-Yu ;
Shih, Jin-Yuan ;
Ho, Chao-Chi ;
Yang, Chih-Hsin ;
Yu, Chong-Jen ;
Yang, Pan-Chyr .
BMC CANCER, 2012, 12
[8]   Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin [J].
Inomata, Minehiko ;
Hayashi, Ryuji ;
Tokui, Kotaro ;
Taka, Chihiro ;
Okazawa, Seisuke ;
Kambara, Kenta ;
Ichikawa, Tomomi ;
Yamada, Toru ;
Miwa, Toshiro ;
Kashii, Tatsuhiko ;
Matsui, Shoko ;
Tobe, Kazuyuki .
TUMORI, 2016, 102 (06) :606-609
[9]  
Inomata M, 2014, TUMORI, V100, P507, DOI 10.1700/1660.18164
[10]   Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer [J].
Jiang, Huihong ;
Li, Huaguang ;
Li, Ajian ;
Tang, Erjiang ;
Xu, Dan ;
Chen, Yin ;
Zhang, Yong ;
Tang, Min ;
Zhang, Zhiyong ;
Deng, Xiaxing ;
Lin, Moubin .
ONCOTARGET, 2016, 7 (44) :72076-72083